- Home
- CCCC vs AGEN Comparison
CCCC vs AGEN Comparison
Compare CCCC & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- AGEN
- Stock Information
- Founded
- CCCC 2015
- AGEN 1994
- Country
- CCCC United States
- AGEN United States
- Employees
- CCCC N/A
- AGEN N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CCCC Health Care
- AGEN Health Care
- Exchange
- CCCC Nasdaq
- AGEN Nasdaq
- Market Cap
- CCCC 405.6M
- AGEN 97.7M
- IPO Year
- CCCC 2020
- AGEN 2000
- Fundamental
- Price
- CCCC $6.25
- AGEN $4.50
- Analyst Decision
- CCCC Buy
- AGEN Buy
- Analyst Count
- CCCC 6
- AGEN 3
- Target Price
- CCCC $10.50
- AGEN $10.00
- AVG Volume (30 Days)
- CCCC 731.1K
- AGEN 346.0K
- Earning Date
- CCCC 10-30-2024
- AGEN 11-05-2024
- Dividend Yield
- CCCC N/A
- AGEN N/A
- EPS Growth
- CCCC N/A
- AGEN N/A
- EPS
- CCCC N/A
- AGEN N/A
- Revenue
- CCCC $29,378,000.00
- AGEN $159,630,000.00
- Revenue This Year
- CCCC $39.70
- AGEN N/A
- Revenue Next Year
- CCCC N/A
- AGEN $0.04
- P/E Ratio
- CCCC N/A
- AGEN N/A
- Revenue Growth
- CCCC 83.26
- AGEN 60.67
- 52 Week Low
- CCCC $1.06
- AGEN $4.18
- 52 Week High
- CCCC $11.88
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- CCCC 54.57
- AGEN 40.31
- Support Level
- CCCC $6.26
- AGEN $4.50
- Resistance Level
- CCCC $7.14
- AGEN $4.78
- Average True Range (ATR)
- CCCC 0.37
- AGEN 0.29
- MACD
- CCCC 0.12
- AGEN 0.02
- Stochastic Oscillator
- CCCC 58.99
- AGEN 30.77
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).